Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell Types

News   Nov 21, 2017

 
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell Types

Human neurons stained for MAP2 and synaptophysin

 
 
 

RELATED ARTICLES

Lonza Expands Encapsulation and HPAPI Capabilities in North America

News

Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.

READ MORE

Protein Analysis Gives Insight into Parkinson's

News

A study has characterized levels of pathological proteins from throughout the bodies of Parkinson's Disease patients, revealing some surprising findings.

READ MORE

Studying Ebola-Host Cell Interaction Helps Find Targets for Antiviral Drugs

News

In some ways, the Ebola virus operates like a vampire; only after it is politely invited in to a host cell does it take up the task of destroying everything in its path. In a new study researchers seek to elucidate quantitatively the biomechanical mechanism of Ebola-host cell interaction, providing potential new targets for antiviral drug development.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Neuroscience

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE